1. Home
  2. KWR vs ZYME Comparison

KWR vs ZYME Comparison

Compare KWR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quaker Houghton

KWR

Quaker Houghton

HOLD

Current Price

$135.46

Market Cap

2.0B

Sector

Industrials

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.76

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KWR
ZYME
Founded
1918
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
KWR
ZYME
Price
$135.46
$26.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
11
Target Price
$167.00
$38.90
AVG Volume (30 Days)
152.0K
517.9K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.52%
N/A
EPS Growth
N/A
33.33
EPS
1.13
N/A
Revenue
$1,888,634,000.00
$105,965,000.00
Revenue This Year
$5.16
$183.10
Revenue Next Year
$3.63
N/A
P/E Ratio
$124.21
N/A
Revenue Growth
2.66
38.87
52 Week Low
$99.18
$10.89
52 Week High
$183.01
$29.75

Technical Indicators

Market Signals
Indicator
KWR
ZYME
Relative Strength Index (RSI) 52.49 49.47
Support Level $133.86 $22.28
Resistance Level $143.53 $27.35
Average True Range (ATR) 5.94 1.03
MACD 0.33 -0.23
Stochastic Oscillator 53.36 11.52

Price Performance

Historical Comparison
KWR
ZYME

About KWR Quaker Houghton

Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: